US FDA approves Mylan and Biocon’s Ogivri
It is the first biosimilar for Trastuzumab, for the treatment of HER2-Positive breast and gastric cancers
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.